Terminated PHASE3 INTERVENTIONAL 4-arm NCT00625898

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab

Sponsor: Cancer International Research Group (CIRG)

Conditions Breast Cancer

Interventions 5-Fluorouracil Bevacizumab Carboplatin Cyclophosphamide Docetaxel Epirubicin Trastuzumab

Updated 9 times since 2017 Last updated: Sep 9, 2020 Started: Apr 30, 2008 Primary completion: Jun 30, 2013 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT00625898, this PHASE3 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Cancer International Research Group (CIRG), it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE3
Sep 2025 — Dec 2025 [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Oct 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Oct 2020 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer International Research Group (CIRG)
Genentech, Inc.
Hoffmann-La Roche
NSABP Foundation Inc

Data source: NSABP Foundation Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Adrian, United States , Akron, United States , Alba Iulia, Romania , Albany, United States , Alcorcón, Spain , Alhambra, United States , Alicante, Spain , Allentown, United States , Alliance, United States and 470 more locations